Distribution of total net revenues

SEK million

2018

Jul-Sep

2017

Jul-Sep

2018

Jan-Sep

2017

Jan-Sep

12 mth

Oct 2017- Sep 2018

12 mth

Oct 2016- Sep 2017

Zubsolv® US

165.4

121.1

454.9

359.3

581.4

487.5

Zubsolv – Rest of the World

0.2

31.0

36.6

Zubsolv – total

165.6

121.1

485.9

359.3

618.0

487.5

Abstral® royalties

48.7

39.4

66.4

57.8

121.8

110.0

Edluar® royalties

2.3

5.7

3.7

13.7

7.3

18.0

OX-CLI

21.8

21.8

Total

216.6

166.2

556.0

452.6

747.1

637.3

 

Key figures

SEK million, unless otherwise stated

2018

Jul-Sep

2017

Jul-Sep

2018

Jan-Sep

2017

Jan-Sep

12 mth

Oct 2017 - Sep 2018

12 mth

Oct 2016 - Sep 2017

 

 

 

 

 

 

 

Net revenues

216.6

166.2

556.0

452.6

747.0

637.3

whereof Zubsolv® US net revenue

165.4

121.1

454.9

359.3

581.4

487.5

Cost of goods sold

-42.4

-32.1

-128.4

-114.1

-178.7

-159.0

Operating expenses

-139.6

-93.2

-369.4

-311.3

-480.0

-428.6

EBIT

34.6

40.9

58.2

27.2

88.2

49.8

EBIT margin, %

16.0

24.6

10.5

6.0

11.8

7.8

US EBIT

55.6

31.8

136.5

54.0

156.2

51.6

US EBIT margin, %

33.6

26.3

30.0

15.0

26.9

10.6

EBITDA

39.8

46.1

73.7

42.8

109.0

67.1

Earnings per share, before dilution, SEK

1.80

0.82

2.50

-0.10

3.27

0.55

Earnings per share, after dilution, SEK

1.77

0.81

2.46

-0.10

3.26

0.55

Cash flow from operating activities

24.5

92.3

170.4

169.6

147.4

241.0

Cash and cash equivalents

516.6

370.7

516.6

370.7

516.6

370.7

Cash flow

Cash flow

MSEK

Q3

2018

Q3

2017

Jan – Sep

2018

Jan - Sep

2017

12 mth

Oct 2017 – Sep 2018

Cash flow from operating activities

24.5

92.3

170.4

169.6

146.6

Investment activities

-0.5

-0.5

-2.2

-0.8

-1.6

Financing activities

-0.1

-

-

-59.0

-85.4

Cash flow (excl exchange rate differences)

23.9

91.8

168.2

109.8

59.6

Liquid funds

516.6

370.7

516.6

370.7

327.9